The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

Me (ME), the company that popularized consumer genetic testing, announced Tuesday that it is once again exploring “strategic ...

The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

1."My Dad is an identical twin. So, all three of my uncle's children should be my half-siblings genetically. They did 23andMe ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year ...

Founded in 2006, 23andMe seized consumer interest with its genetic-testing kits that offered customers breakdowns of their ancestry. In 2017, it started selling tests designed to help assess a ...

The genetic testing company ended last year with $79.4 million and told investors it will need to raise money to fund its operations and financial commitments.